Posts

Garijo’s Plan to Revamp Sanofi: R&D Cleanup, More M&A, and a China Push Explained

on

Sanofi floats flu shot marketing pledges to pacify EU antitrust probe

on

Recordati licenses Ionis drug

on

FDA panel strongly backs Moderna's mRNA flu vaccine for older adults, with final decision expected by early August 2026.

on

Elicio pancreatic cancer vaccine misses Phase II primary endpoint but shows post-hoc signal in resected patients

on

US FDA advisers to weigh updating 2026-27 COVID vaccines for XFG variant

on

CDER chief Høeg, skeptic of vaccines and antidepressants, is fired in high-level FDA shakeup

on

Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand

on

BioNTech Shuts Down COVID Vaccine Production, Closing Sites and Cutting 1,860 Jobs

on

Live Friday: CDC Ends Universal COVID-19 Vaccine Recommendation – Anti-Vax Shift Under RFK Jr.?

on

MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation

on

FDA's Vinay Prasad to Depart as Head of Vaccines and Biologics Division Amid Controversy

on

Pfizer and Valneva's Lyme Vaccine Misses Primary Endpoint But Pursue Regulatory Approval

on

Federal Judge Blocks RFK Jr.'s Childhood Vaccine Policy Overhaul

on

Moderna Agrees to Pay Up to $2.25 Billion to Settle COVID-19 Vaccine Patent Dispute with Arbutus and Roivant Subsidiary Genevant

on

CHMP Recommends Moderna's mCombriax Flu-COVID Vaccine for Adults 50+

on

FDA Reverses Course on Moderna's mRNA Flu Vaccine Application After Initial Rejection

on

FDA Reverses Course and Agrees to Review Moderna's mRNA Flu Vaccine

on

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

on

Moderna's Outright Flu Refusal Just the Latest Case of Crossed FDA Signals

on